Pfizer has secured approval from the US Food and Drug Administration (FDA) for its drug Trazimera (trastuzumab-qyyp), a biosimilar medicine to Roche’s Herceptin (trastuzumab).
Daiichi Sankyo announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201)....
The combination of digital mammography (DM) and digital breast tomosynthesis (DBT) detects 90 percent more breast cancers than digital mammography alone, according to a study published in the August issue of Radiology.